• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SNDX

    Syndax Pharmaceuticals Inc.

    Subscribe to $SNDX
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

    IPO Year: 2016

    Exchange: NASDAQ

    Website: syndax.com

    Peers

    $KALA
    $MRUS
    $CDAK

    Recent Analyst Ratings for Syndax Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    10/24/2024$37.00Buy
    UBS
    6/28/2024$37.00Buy
    Jefferies
    1/31/2024$36.00 → $23.00Sector Outperform → Sector Perform
    Scotiabank
    12/22/2023$45.00Buy
    Mizuho
    10/25/2023$29.00Buy
    BofA Securities
    10/11/2023$30.00Buy
    Goldman
    7/27/2023Sector Outperform
    Scotiabank
    7/11/2023$40.00Buy
    Guggenheim
    4/17/2023$34.00Buy
    BTIG Research
    1/31/2023$37.00Buy
    Stifel
    See more ratings

    Syndax Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Syndax Announces Participation in May Investor Conferences

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Bank of America Merrill Lynch Vegas Health Care Conference with a fireside chat on Thursday, May 15, 2025, at 9:20 a.m. PT/ 12:20 p.m. ET.TD Cowen 6th Annual Oncology Innovation Summit with a virtual fireside chat on Wednesday, May 28, 2025, at 10:30 a.m. ET. A live webcast of the fireside chats will be available in the Investor section o

      5/8/25 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

      – Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML submitted in April 2025 – NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, a first-in-class menin inhibitor, in patients with relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) have been published in

      5/7/25 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

      – $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – Initiated a pivotal frontline trial of revumenib plus ven/aza in mNPM1 and KMT2Ar AML – – $602.1 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, toda

      5/5/25 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2025 the Company granted inducement awards to purchase up to 188,100 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About Syn

      5/2/25 4:05:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 5, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 5, 2025 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alt

      4/28/25 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2025 the Company granted inducement awards to purchase up to 50,000 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting

      4/4/25 4:05:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

      NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceuti

      4/2/25 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted inducement awards to purchase up to 282,000 shares of common stock to 12 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting

      3/5/25 4:05:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      – $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial – – $692.4 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 8:00 a.m. ET – NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its finan

      3/3/25 7:01:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Announces Participation in March Investor Conferences

      WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside chat on Tuesday, March 4, 2025, at 3:10 p.m. ETBarclays 27th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Thursday, March 13, 2025, at 8:30 a.m. ET A live webcast of the fireside chats will be available

      2/25/25 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syndax Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Goldan Keith A. bought $25,037 worth of shares (1,250 units at $20.03), increasing direct ownership by 2% to 52,623 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      6/17/24 9:26:27 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syndax Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Metzger Michael A exercised 6,074 shares at a strike of $7.20, increasing direct ownership by 2% to 306,195 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      3/17/25 6:01:11 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Metzger Michael A exercised 7,814 shares at a strike of $7.20 and sold $117,564 worth of shares (7,814 units at $15.05) (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      3/6/25 4:10:30 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Goldan Keith A. sold $58,559 worth of shares (3,777 units at $15.50), decreasing direct ownership by 4% to 90,746 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      2/12/25 5:16:46 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Metzger Michael A sold $206,017 worth of shares (13,288 units at $15.50), decreasing direct ownership by 4% to 300,121 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      2/12/25 5:15:20 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, Head of R&D Gallagher Neil sold $71,597 worth of shares (4,618 units at $15.50), decreasing direct ownership by 5% to 85,095 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      2/12/25 5:13:24 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, Head of R&D Gallagher Neil was granted 41,900 shares, increasing direct ownership by 88% to 89,713 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      2/7/25 4:45:49 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Goldan Keith A. was granted 41,900 shares, increasing direct ownership by 80% to 94,523 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      2/7/25 4:44:26 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Metzger Michael A was granted 149,500 shares, increasing direct ownership by 91% to 313,409 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      2/7/25 4:42:46 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Podlesak Dennis was granted 50,000 shares, increasing direct ownership by 35% to 191,763 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      2/7/25 4:41:27 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Rizo Aleksandra was granted 25,000 shares (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      2/7/25 4:39:46 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syndax Pharmaceuticals Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

      Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity

      11/18/24 9:22:42 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syndax Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    Syndax Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

      SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      11/8/24 10:52:38 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

      SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      10/18/24 11:49:10 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.

      SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      2/14/24 12:50:09 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      2/14/24 7:01:19 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      2/13/24 9:44:01 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.

      SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      2/13/24 5:15:54 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      2/8/24 10:18:47 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      1/25/24 4:59:24 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      1/25/24 11:20:06 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.

      SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      10/31/23 4:26:52 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Syndax Pharmaceuticals with a new price target

      UBS initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00

      10/24/24 6:28:31 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Syndax Pharmaceuticals with a new price target

      Jefferies initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00

      6/28/24 8:13:58 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals downgraded by Scotiabank with a new price target

      Scotiabank downgraded Syndax Pharmaceuticals from Sector Outperform to Sector Perform and set a new price target of $23.00 from $36.00 previously

      1/31/24 7:22:33 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on Syndax Pharmaceuticals with a new price target

      Mizuho initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $45.00

      12/22/23 7:30:38 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Syndax Pharmaceuticals with a new price target

      BofA Securities initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $29.00

      10/25/23 7:11:56 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Syndax Pharmaceuticals with a new price target

      Goldman initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $30.00

      10/11/23 7:45:47 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Syndax Pharmaceuticals

      Scotiabank initiated coverage of Syndax Pharmaceuticals with a rating of Sector Outperform

      7/27/23 7:37:22 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Syndax Pharmaceuticals with a new price target

      Guggenheim initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $40.00

      7/11/23 7:40:06 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research resumed coverage on Syndax Pharmaceuticals with a new price target

      BTIG Research resumed coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $34.00

      4/17/23 9:08:39 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Syndax Pharmaceuticals with a new price target

      Stifel initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00

      1/31/23 6:27:35 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syndax Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

      – $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – Initiated a pivotal frontline trial of revumenib plus ven/aza in mNPM1 and KMT2Ar AML – – $602.1 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, toda

      5/5/25 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 5, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 5, 2025 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alt

      4/28/25 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      – $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial – – $692.4 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 8:00 a.m. ET – NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its finan

      3/3/25 7:01:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

      WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 8:00 a.m. ET on Monday, March 3, 2025 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section o

      2/24/25 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

      – Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients – – 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort – – 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML – – BEAT AML data highlight the potential for revumenib to advance the current standard of care – WALTHAM, Mass., Dec. 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company develop

      12/9/24 7:30:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

      –        82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML – –        64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to proceed to HSCT in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 – –         Responses were rapid, durable and observed across all major subgroups in expanded dataset ofPh 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 – –         Latest data highlight the compelling clinical profile of revumenib and support advancement into combination trials in the frontline setting – WALTHAM, Mass.

      12/7/24 6:15:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

      – Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – – Syndax to host conference call today at 6:00 p.m. ET – WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therap

      11/15/24 5:29:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

      –      Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) – –      47% (30/64) ORR in a heavily pre-treated population, including 75% with prior venetoclax exposure in the efficacy population – –      Favorable safety and tolerability profile; only 5% of patients discontinued due to treatment-related adverse events – –      Results highlight consistency of revumenib's compelling clinical profile – –      sNDA filing in R/R mNPM1 AML expected in 1H25, pending anticipated FDA approval of revumenib in R/R KMT2Ar acute leukemia in 4Q24 – –      Syndax to host a conference call today at 8:00 am ET – WALTHAM, Mass., Nov. 12, 2024 /PRNew

      11/12/24 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update

      –  New revumenib and Niktimvo™ clinical data will be highlighted at 66th ASH Annual Meeting – – mNPM1 AML topline data from AUGMENT-101 expected in 4Q24; potential sNDA filing in 1H25 – – Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – – Niktimvo approved by U.S. FDA for treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg – –  $350 million royalty funding agreement for Niktimvo expected to fund Company through profitability – – Company to host a conference call today at 4:30 p.m. ET – WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax

      11/5/24 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024

      WALTHAM, Mass., Oct. 29, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2024 financial results and provide a business update on Tuesday, November 5, 2024. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, November 5, 2024 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's we

      10/29/24 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syndax Pharmaceuticals Inc. SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.

      SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      5/9/25 12:34:37 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.

      SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      5/7/25 11:25:22 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Syndax Pharmaceuticals Inc.

      10-Q - Syndax Pharmaceuticals Inc (0001395937) (Filer)

      5/5/25 4:04:25 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)

      5/5/25 4:02:39 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Syndax Pharmaceuticals Inc.

      DEFA14A - Syndax Pharmaceuticals Inc (0001395937) (Filer)

      4/1/25 4:03:03 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Syndax Pharmaceuticals Inc.

      DEF 14A - Syndax Pharmaceuticals Inc (0001395937) (Filer)

      4/1/25 4:01:16 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.

      SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      3/7/25 11:13:24 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Syndax Pharmaceuticals Inc.

      144 - Syndax Pharmaceuticals Inc (0001395937) (Subject)

      3/4/25 5:10:13 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Syndax Pharmaceuticals Inc.

      S-8 - Syndax Pharmaceuticals Inc (0001395937) (Filer)

      3/4/25 9:18:39 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Syndax Pharmaceuticals Inc.

      10-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)

      3/3/25 7:05:11 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syndax Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

      BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex

      6/10/24 7:30:00 AM ET
      $PYXS
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

      WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D., Ph.D., to its Board of Directors. Dr. Rizo has extensive clinical development experience and a track record of successfully leading the development of several hematology drugs from discovery through commercialization. She will serve as a member of the Science and Technology Committee of the Board. Dr. Rizo will replace Dr. Briggs Morrison who will step down effective May 14, 2024 after a successful 9-year tenure as a member of the Company's Board of Directo

      5/15/24 4:05:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

      VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024. "Dr. Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company's development and growth," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "His exp

      3/28/24 6:00:00 AM ET
      $SNDX
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

      – Steven Closter brings more than 30 years of commercial experience in the biopharmaceutical industry to Syndax – – Company on track for two potential first- and best-in-class product launches in 2024 – WALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately. Mr. Closter will lead the Company's commercial strategy and operations, including marketing, sales, and market access, succeeding Steve Sabus, who is departing for personal reasons. "Steven Closter is an accompl

      3/18/24 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development

      - Neil Gallagher, M.D., Ph.D. brings to Syndax over 20 years of experience as a leading oncology drug developer - WALTHAM, Mass., March 30, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Neil Gallagher, M.D., Ph.D., to the role of President, Head of Research and Development (R&D), effective April 10, 2023. Dr. Gallagher brings to Syndax over 20 years of industry experience, most recently serving as Chief Medical Officer, Vice President, Head of Development at AbbVie, where he led multiple development programs through approval globally and over

      3/30/23 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

      WALTHAM, Mass., Dec. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5, 2022. Mr. Sabus brings to Syndax more than 30 years of commercial experience launching drugs and building sales and marketing organizations within the biopharmaceutical industry. As Chief Commercial Officer, Mr. Sabus will oversee all commercial functions, including the development of critical launch initiatives, sales planning and commercial strategy. "Steve is an accomplished executive who has laun

      12/2/22 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer

      WALTHAM, Mass., June 13, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Keith A. Goldan to the role of Chief Financial Officer, effective immediately. Mr. Goldan, who brings to Syndax nearly thirty years of leadership and operational experience at several pharmaceutical, biotechnology, and medical technology companies, most recently served as Chief Financial Officer at Optinose®, where he helped build the infrastructure to support the launch of XHANCE® (fluticasone propionate) in the United States. As Chief Fi

      6/13/22 7:30:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer

      WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Kate Madigan, M.D., to the role of Chief Medical Officer, effective immediately. Dr. Madigan, who brings to Syndax over 20 years of clinical hematology expertise and broad experience in the design and execution of early to late-stage clinical programs across oncology and rare diseases, will lead the Company's clinical development strategy. She will succeed Michael Meyers, M.D., Ph.D., who will continue with the Company through June before

      3/1/22 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michaela Bowden, PhD, as SVP of Biology and Translation

      Company expands leadership team across business and science as it advances precision oncology pipeline Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Daphne Karydas as Chief Operating Officer and Chief Financial Officer, and Michaela Bowden, PhD, as Senior Vice President of Biology and Translation. "We are thrilled to be growing Flare's executive team with the appointment of these two outstanding and accomplished industry leaders, deepening our expertise in areas of business and science and positioning Flare for growth," said Abbie Celniker, PhD, interim Chief Exe

      10/25/21 8:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Appoints Martin H. Huber, M.D., to its Board of Directors

      WALTHAM, Mass., Sept. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the expansion of its Board of Directors to nine members with the appointment of Martin H. Huber, M.D., effective today. Dr. Huber has over 20 years of academic, biotechnology, and pharmaceutical drug development experience, currently serving as the President of R&D and Chief Medical Officer of Xilio Therapeutics, Inc. "It is my pleasure to welcome industry veteran, Dr. Marty Huber, to the Syndax team," said Dennis Podlesak, Chair of the Board at Syndax. "A

      9/15/21 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care